Lansoprazol Cin Cinfamed

Lansoprazole, the active ingredient in Lansoprazol Cin Cinfamed, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related gastrointestinal conditions such as reflux disease and ulcers. GNH USA supplies Lansoprazol Cin Cinfamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to treat disorders associated with excess gastric acid. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by lowering acid exposure. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through acid suppression. - Helicobacter pylori eradication: enhances antibiotic efficacy when used as part of combination therapy. - Erosive esophagitis: facilitates mucosal healing by reducing reflux‑related injury.

Adverse reactions may occur with lansoprazole use.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea, abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in severe impairment. - Evaluate hepatic status: use cautiously in liver disease. - Monitor long‑term use: prolonged therapy may increase fracture risk. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect; consider alternative therapy. - Atazanavir: markedly decreased antiviral exposure; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: increased serum levels; observe for toxicity signs. - Methotrexate (high dose): reduced clearance; check renal function and drug levels.